Sensei Biotherapeutics Inc Total Assets
Sensei Biotherapeutics Inc total assets. Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) holds total assets worth $205.38 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see SNSE market cap for the company's overall valuation and market capitalisation.
Total Assets of Sensei Biotherapeutics Inc (2018–2025)
Total assets of Sensei Biotherapeutics Inc from 2018 to 2025. This chart illustrates how Sensei Biotherapeutics Inc's total assets have evolved over time, based on quarterly financial data. See SNSE stock price and chart for real-time trading data and today's change.
Sensei Biotherapeutics Inc - Asset Composition Analysis
Sensei Biotherapeutics Inc Total Assets Breakdown (December 2025)
Sensei Biotherapeutics Inc total assets breakdown as of December 2025. Sensei Biotherapeutics Inc's total assets of $205.38 Million consist of 93.9% current assets and 6.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 37.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2018–2025)
This chart illustrates how Sensei Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SNSE current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sensei Biotherapeutics Inc's current assets represent 93.9% of total assets in 2025, an increase from 69.2% in 2018.
- Cash Position: Cash and equivalents constituted 37.9% of total assets in 2025, up from 35.3% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Sensei Biotherapeutics Inc Competitors by Total Assets
Key competitors of Sensei Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Sensei Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 14.39 | 6.82 | 42.22 |
| Quick Ratio | 14.39 | 6.82 | 42.22 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $190.04 Million | $30.45 Million | $161.69 Million |
Sensei Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Sensei Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.26 |
| Latest Market Cap to Assets Ratio | 0.81 |
| Asset Growth Rate (YoY) | -49.5% |
| Total Assets | $22.90 Million |
| Market Capitalization | $18.59 Million USD |
Valuation Analysis
Near Book Valuation: The market values Sensei Biotherapeutics Inc's assets close to their book value (0.81x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Sensei Biotherapeutics Inc's assets decreased by 49.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sensei Biotherapeutics Inc (2018–2025)
The table below shows the annual total assets of Sensei Biotherapeutics Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $22.90 Million | -49.51% |
| 2024-12-31 | $45.36 Million | -39.01% |
| 2023-12-31 | $74.37 Million | -37.17% |
| 2022-12-31 | $118.38 Million | -22.74% |
| 2021-12-31 | $153.22 Million | +615.07% |
| 2020-12-31 | $21.43 Million | +1660.72% |
| 2019-12-31 | $1.22 Million | -34.22% |
| 2018-12-31 | $1.85 Million | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune … Read more